NEW YORK, August 16, 2017 /PRNewswire/ --
If you want a Stock Review on ARLZ, ARNA, ARWR, or AVIR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Companies in the Biotech space are engaged in the research and development of biological substances, primarily for the purpose of drug discovery and diagnostic development. The majority of their revenue is derived from either the sale or licensing of drugs and diagnostic tools. Today, DailyStockTracker.com has initiated coverage on Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Aviragen Therapeutics Inc. (NASDAQ: AVIR). These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
Milton, Canada headquartered Aralez Pharmaceuticals Inc.'s stock finished Tuesday's session 6.14% lower at $1.07. A total volume of 722,396 shares was traded, which was above their three months average volume of 684,120 shares. The Company's shares are trading below their 50-day moving average by 16.28%. Moreover, shares of Aralez Pharma, which operates as a specialty pharmaceutical company in Canada, Ireland, and the US, have a Relative Strength Index (RSI) of 40.52.
On August 09th, 2017, Aralez Pharma announced financial results for Q2 2017 and H1 2017. For Q2 2017, total revenues were $27.6 million; SG&A costs were $32.2 million; and net loss was $27.5 million. For H1 2017, total revenues were $53.6 million; SG&A costs were $63.1 million; and net loss was $55.0 million.
On August 10th, 2017, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $5.50 a share to $4 a share. Your complete research report on ARLZ can be retrieved for free at:
Shares in San Diego, California-based Arena Pharmaceuticals Inc. declined 0.56%, ending yesterday's session at $21.27 with a total trading volume of 357,376 shares. The stock has surged 78.74% in the previous three months and 49.79% on an YTD basis. The Company's shares are trading 9.68% above their 50-day moving average and 35.92% above their 200-day moving average. Moreover, shares of Arena Pharma, which focuses on developing novel small molecule drugs for various therapeutic areas in the US and Switzerland, have an RSI of 49.00.
On August 07th, 2017, Arena Pharma reported financial results for Q2 ended June 30th, 2017. Revenues totaled $6.5 million; R&D expenses totaled $17.9 million; G&A expenses totaled $7.2 million; and net loss was $23.6 million. At June 30th, 2017, cash and cash equivalents totaled $130.8 million, and approximately 31.8 million shares of the Company's common stock were outstanding. A free report on ARNA is just a click away at:
On Tuesday, Pasadena, California headquartered Arrowhead Pharmaceuticals Inc.'s stock closed the day flat at $1.94. A total volume of 281,150 shares was traded. The Company's shares have advanced 25.16% in the last one month, 11.49% in the previous three months, and 25.16% on an YTD basis. The stock is trading 16.77% above its 50-day moving average. Additionally, shares of Arrowhead Pharma, which develops novel drugs to treat intractable diseases in the US, have an RSI of 60.49.
On August 03rd, 2017, Arrowhead Pharma announced financial results for its Q3 FY17 ended June 30th, 2017. Revenue for the quarter was $9.3 million, total operating expenses were $15.1 million, and net loss was $5.5 million. At June 30th, 2017, cash and short-term investments combined totaled $75.1 million. Sign up for your complimentary research report on ARWR at:
Shares in Alpharetta, Georgia headquartered Aviragen Therapeutics Inc. ended the day 1.69% lower at $0.58. A total volume of 44,007 shares was traded. The stock has gained 16.00% in the previous three months. The Company's shares are trading above their 50-day moving average by 0.56%. Furthermore, shares of Aviragen Therapeutics, which focuses on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect patients worldwide, have an RSI of 48.86.
Register for free on DailyStockTracker.com and download the latest research report on AVIR at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA